Predictors of restenosis after percutaneous coronary intervention using bare-metal stents. A comparison between patients with and without dysglycemia

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 6, 2010, Pages 572-579

  Lima Filho, M O ^a   Figueiredo, G L ^a   Foss Freitas, M C ^a   Foss, M C ^a   Marin Neto, J A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Coronary restenosis; Coronary stents; Diabetes mellitus; Dysglycemia; Insulin resistance

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULINEMIA; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; RESTENOSIS;

EID: 77953926260     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500051     Document Type: Article

References (40)

1. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118: 344-349.
2. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589.
3. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-1873.
4. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082-2089.
5. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997; 95: 1366-1369.
6. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528-535.
7. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A metaanalysis of prospective studies. Arch Intern Med 2004; 164: 2147-2155.
8. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23: 1267-1275.
9. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
10. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
11. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
12. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
13. Nishimoto Y, Miyazaki Y, Toki Y, Murakami R, Shinoda M, Fukushima A, et al. Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina. J Am Coll Cardiol 1998; 32: 1624-1629.
14. Nishio K, Fukui T, Tsunoda F, Kawamura K, Itoh S, Konno N, et al. Insulin resistance as a predictor for restenosis after coronary stenting. Int J Cardiol 2005; 103: 128-134.
15. Sekiguchi M, Kurabayashi M, Adachi H, Hoshizaki H, Oshima S, Taniguchi K. Usefulness of insulin resistance measured by homeostasis model assessment in predicting restenosis after coronary stent placement in nondiabetic patients. Am J Cardiol 2004; 93: 920-922.
16. Takagi T, Yoshida K, Akasaka T, Kaji S, Kawamoto T, Honda Y, et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 731-738.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
18. Reiber JH, Koning G, Goedhart B. The effect of DICOM on QCA and clinical trials. Int J Card Imaging 1998; 14 (Suppl 1): 7-12.
19. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 1478-1492.
20. Muhlestein JB, Anderson JL, Horne BD, Lavasani F, len Maycock CA, Bair TL, et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003; 146: 351-358.
21. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
22. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
23. Corpus RA, O'Neill WW, Dixon SR, Timmis GC, Devlin WH. Relation of hemoglobin A1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol 2003; 92: 1282-1286.
24. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43: 8-14.
25. Kauffman AB, Delate T, Olson KL, Cymbala AA, Hutka KA, Kasten SL, et al. Relationship between haemoglobin A1C values and recurrent cardiac events: A retrospective, longitudinal cohort study. Clin Drug Investig 2008; 28: 501-507.
26. Lemesle G, Bonello L, de Labriolle A, Maluenda G, Syed AI, Collins SD, et al. Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol 2009; 104: 41-45.
27. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: report of a WHO consultation: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
28. Gaudet D, Vohl MC, Perron P, Tremblay G, Gagne C, Lesiege D, et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 1998; 97: 871-877.
29. Reaven GM, Chen YD. Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit? Circulation 1996; 93: 1780-1783.
30. Rabbani LE, Edelman ER, Ganz P, Selwyn AP, Loscalzo J, Bittl JA. Relation of restenosis after excimer laser angioplasty to fasting insulin levels. Am J Cardiol 1994; 73: 323-327.
31. Radke PW, Voswinkel M, Reith M, Kaiser A, Haager PK, Hanrath P, et al. Relation of fasting insulin plasma levels to restenosis after elective coronary stent implantation in patients without diabetes mellitus. Am J Cardiol 2004; 93: 639-641.
32. Kim SH, Reaven GM. Insulin resistance and hyperinsulinemia: you can't have one without the other. Diabetes Care 2008; 31: 1433-1438.
33. Suselbeck T, Latsch A, Siri H, Gonska B, Poerner T, Pfleger S, et al. Role of vessel size as a predictor for the occurrence of in-stent restenosis in patients with diabetes mellitus. Am J Cardiol 2001; 88: 243-247.
34. Morino Y, Honda Y, Okura H, Oshima A, Hayase M, Bonneau HN, et al. An optimal diagnostic threshold for minimal stent area to predict target lesion revascularization following stent implantation in native coronary lesions. Am J Cardiol 2001; 88: 301-303.
35. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 2004; 43: 1959-1963.
36. Hoffmann R, Mintz GS, Mehran R, Pichard AD, Kent KM, Satler LF, et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol 1998; 31: 43-49.
37. de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation 1999; 100: 1777-1783.
38. Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, et al. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med 2008; 9: 156-165.
39. Paiva MS, Serrano CV Jr, Nicolau JC, Jalbut BO, Fernandes JL, De Lemos JA, et al. Differences in the inflammatory response between patients with and those without diabetes mellitus after coronary stenting. J Interv Cardiol 2008; 21: 403-409.
40. Mulukutla SR, Vlachos HA, Marroquin OC, Selzer F, Holper EM, Abbott JD, et al. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv 2008; 1: 139-147.